E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Macular Telangiectasia Type 1 (MacTel 1) |
|
E.1.1.1 | Medical condition in easily understood language |
Macular Telangiectasia Type 1 is a rare retinal disease characterized by abnormal blood vessels in the central part of the back of the eye (the macula), the cause of which is unknown |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Eye Diseases [C11] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10038899 |
E.1.2 | Term | Retinal telangiectasia |
E.1.2 | System Organ Class | 10015919 - Eye disorders |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the efficacy and safety of THR-317 for the treatment of MacTel 1 |
|
E.2.2 | Secondary objectives of the trial |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Male or female aged 18 years or older
- Macular oedema caused by MacTel 1, with Central Subfield Thickness (CST) >300μm on spectral domain optical coherence tomography (SD-OCT)
- Written informed consent obtained from the subject prior to study procedures
|
|
E.4 | Principal exclusion criteria |
- Type 1 or type 2 diabetes
- Medical history suggesting telangiectasia due to causes other than MacTel 1
- Concurrent disease in the study eye that could require medical or surgical intervention during the study period up to 30 days after the last study treatment, or could confound interpretation of the results
- Previous treatments / procedures as listed below, or their planned / expected use during the study period for up to 30 days after the last study treatment:
* Anti-vascular endothelial growth factor (anti-VEGF) treatment in the study eye (1 month)
* Intraocular surgery in the study eye (3 months)
* Laser photocoagulation in the study eye (3 months)
* Intraocular or periocular corticosteroids in the study eye (4 months)
* Ozurdex® (dexamethasone intravitreal implant) in the study eye (6 months)
* Other steroid implant in the study eye (any time)
- Uncontrolled glaucoma in the study eye
- Any active ocular / intraocular infection or inflammation in either eye
- Pregnant or lactating female
- Female of child-bearing potential not utilising an adequate form of contraception, or planning to become pregnant or to discontinue contraceptive precautions at any time during the entire study period
- Male of reproductive potential not utilising contraception
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Change from baseline in CST |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
- Change from baseline in CST, based on SD-OCT, by study visit
- Change from baseline area of cystoid spaces, based on SD-OCT, by study visit
- Change from baseline in BCVA, by study visit
- Incidence of systemic and ocular (serious) adverse events ([S]AEs), from first study treatment up to the end of the study |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
From first administration of study treatment up to end of study |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |